RenovoRx (RNXT) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 07, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-40738
Entity Registrant Name	RENOVORX, INC.
Entity Central Index Key	0001574094
Entity Tax Identification Number	27-1448452
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4546 El Camino Real
Entity Address, Address Line Two	Suite B1
Entity Address, City or Town	Los Altos
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94022
City Area Code	(650)
Local Phone Number	284-4433
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RNXT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,001,339
Entity Listing, Par Value Per Share	$ 0.0001

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 9,563	$ 1,173
Prepaid expenses and other current assets	468	192
Deferred offering costs		101
Total assets	10,031	1,466
Current liabilities:
Accounts payable	686	561
Accrued expenses	1,086	614
Total current liabilities	1,772	1,175
Common stock warrant liability	1,188	3,291
Total liabilities	2,960	4,466
Commitments and contingencies (Note 5)
Stockholders’ equity (deficit):
Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of September 30, 2024, and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024, and December 31, 2023
Common stock, $0.0001 par value, 250,000,000 shares authorized at September 30, 2024, and December 31, 2023; 24,001,339 and 10,693,580 shares issued and outstanding as of September 30, 2024, and December 31, 2023, respectively	2	1
Additional paid-in capital	54,410	38,404
Accumulated deficit	(47,341)	(41,405)
Total stockholders’ equity (deficit)	7,071	(3,000)
Total liabilities and stockholders’ equity (deficit)	$ 10,031	$ 1,466

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	24,001,339	10,693,580
Common stock, shares outstanding	24,001,339	10,693,580

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 1,650	$ 1,629	$ 4,449	$ 4,892
General and administrative	1,178	1,354	3,889	4,727
Total operating expenses	2,828	2,983	8,338	9,619
Loss from operations	(2,828)	(2,983)	(8,338)	(9,619)
Other income/(expenses), net:
Interest and dividend income	124	43	299	97
Change in fair value of common warrant liability	233	1,519	2,103	3,092
Transaction costs allocated to common warrant liability				(575)
Total other income/(expenses), net	357	1,562	2,402	2,614
Net loss	$ (2,471)	$ (1,421)	$ (5,936)	$ (7,005)
Net loss per share, basic	$ (0.10)	$ (0.13)	$ (0.28)	$ (0.69)
Net loss per share, diluted	$ (0.10)	$ (0.13)	$ (0.28)	$ (0.69)
Weighted-average shares of common stock outstanding, basic	24,940,746	10,693,080	21,325,695	10,154,914
Weighted-average shares of common stock outstanding, diluted	24,940,746	10,693,080	21,325,695	10,154,914

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022		$ 1	$ 37,318	$ 17	$ (31,173)	$ 6,163
Balance, shares at Dec. 31, 2022		9,097,701
Issuance of common stock upon exercise of stock options			6			6
Issuance of common stock upon exercise of stock options, shares		3,547
Stock-based compensation expense			244			244
Net loss					(3,257)	(3,257)
Issuance of restricted stock awards			117			117
Issuance of restricted stock awards, shares		30,000
Other comprehensive loss				(17)		(17)
Balance at Mar. 31, 2023		$ 1	37,685		(34,430)	3,256
Balance, shares at Mar. 31, 2023		9,131,248
Balance at Dec. 31, 2022		$ 1	37,318	17	(31,173)	6,163
Balance, shares at Dec. 31, 2022		9,097,701
Net loss						(7,005)
Balance at Sep. 30, 2023		$ 1	38,183		(38,178)	6
Balance, shares at Sep. 30, 2023		10,693,080
Balance at Mar. 31, 2023		$ 1	37,685		(34,430)	3,256
Balance, shares at Mar. 31, 2023		9,131,248
Issuance of common stock upon exercise of stock options			2			2
Issuance of common stock upon exercise of stock options, shares		4,200
Proceeds from private placement offering, net of offering costs and Issuance of common stock upon the registered direct offering
Proceeds from private placement offering, net of offering costs and Issuance of common stock upon the registered direct offering, shares		1,000,000
Stock-based compensation expense			257			257
Net loss					(2,327)	(2,327)
Issuance and exercise of pre-funded common warrants upon the registered direct offering
Issuance and exercise of pre-funded common warrants upon the registered direct offering, shares		557,632
Balance at Jun. 30, 2023		$ 1	37,944		(36,757)	1,188
Balance, shares at Jun. 30, 2023		10,693,080
Stock-based compensation expense			239			239
Net loss					(1,421)	(1,421)
Balance at Sep. 30, 2023		$ 1	38,183		(38,178)	6
Balance, shares at Sep. 30, 2023		10,693,080
Balance at Dec. 31, 2023		$ 1	38,404		(41,405)	(3,000)
Balance, shares at Dec. 31, 2023		10,693,580
Issuance of common stock upon exercise of stock options			42			42
Issuance of common stock upon exercise of stock options, shares		38,981
Proceeds from private placement offering, net of offering costs and Issuance of common stock upon the registered direct offering		$ 1	5,377			5,378
Proceeds from private placement offering, net of offering costs and Issuance of common stock upon the registered direct offering, shares		6,133,414
Stock-based compensation expense			423			423
Net loss					(1,076)	(1,076)
Balance at Mar. 31, 2024		$ 2	44,246		(42,481)	1,767
Balance, shares at Mar. 31, 2024		16,865,975
Balance at Dec. 31, 2023		$ 1	38,404		(41,405)	$ (3,000)
Balance, shares at Dec. 31, 2023		10,693,580
Issuance of common stock upon exercise of stock options, shares						93,481
Net loss						$ (5,936)
Balance at Sep. 30, 2024		$ 2	54,410		(47,341)	7,071
Balance, shares at Sep. 30, 2024		24,001,339
Balance at Mar. 31, 2024		$ 2	44,246		(42,481)	1,767
Balance, shares at Mar. 31, 2024		16,865,975
Issuance of common stock upon exercise of stock options			12			12
Issuance of common stock upon exercise of stock options, shares		23,228
Proceeds from private placement offering, net of offering costs and Issuance of common stock upon the registered direct offering			9,638			9,638
Proceeds from private placement offering, net of offering costs and Issuance of common stock upon the registered direct offering, shares		6,960,864
Stock-based compensation expense			244			244
Net loss					(2,389)	(2,389)
Issuance of restricted stock awards
Issuance of restricted stock awards, shares		120,000
Balance at Jun. 30, 2024		$ 2	54,140		(44,870)	9,272
Balance, shares at Jun. 30, 2024		23,970,067
Issuance of common stock upon exercise of stock options			15			15
Issuance of common stock upon exercise of stock options, shares		31,272
Stock-based compensation expense			255			255
Net loss					(2,471)	(2,471)
Balance at Sep. 30, 2024		$ 2	$ 54,410		$ (47,341)	$ 7,071
Balance, shares at Sep. 30, 2024		24,001,339

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (5,936)	$ (7,005)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	922	857
Change in fair value of common warrants classified as a liability	(2,103)	(3,092)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(276)	573
Deferred offering costs	101	(41)
Accounts payable	125	(184)
Accrued expenses	472	687
Net cash used in operating activities	(6,695)	(8,205)
Cash flows from investing activities:
Proceeds from sale of investments		2,032
Net cash provided by investing activities		2,032
Cash flows from financing activities:
Proceeds from private placement offering, net of offering costs	15,016	5,000
Proceeds from exercise of stock options	69	8
Net cash provided by financing activities	15,085	5,008
Net increase/(decrease) in cash and cash equivalents	8,390	(1,165)
Beginning of period	1,173	4,391
End of period	9,563	3,226
Supplemental disclosure of non-cash financing activities:
Fair value of common warrant classified as a liability	$ 1,188	$ 1,908

Business and Principal Activiti

Business and Principal Activities	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Principal Activities	1. Business and Principal Activities Description of Business RenovoRx, Inc. (the “Company,” “we,” “us,” “our” and similar terminology) was incorporated in the state of Delaware in December 2012 and operates from its headquarters in Los Altos, California. The Company is a life sciences company developing novel targeted oncology therapies and offering RenovoCath® The Company’s patented Trans-Arterial Micro-Perfusion (“TAMP™”) The Company’s lead product candidate is a novel oncology drug-device combination product being investigated under a U.S. Investigational New Drug (“IND”) application that is regulated by the FDA’s 21 CFR 312 pathway. The investigational drug-device combination candidate utilizes RenovoCath The intra-arterial infusion of the chemotherapy gemcitabine utilizing RenovoCath is currently being evaluated for the treatment of locally advanced pancreatic cancer (“LAPC”) by the Center for Drug Evaluation and Research (the drug division of FDA) in our ongoing Phase III TIGeR-PaC clinical trial. Liquidity and Capital Resources From the Company’s inception through September 30, 2024, it has raised an aggregate of $ 59.2 53.8 9.6 0.0001 The Company is in the pre-commercial stage and therefore has incurred significant losses and negative cash flows from operations since its inception. For the nine months ended September 30, 2024, the Company reported a net loss of $ 5.9 47.3 marketing its proprietary catheter device on a standalone basis The Company believes it will be able to raise additional required capital through debt financings, private or public equity financings, license agreements, collaborative agreements or other arrangements with other companies, or other sources of financing. There can be no assurance that such financing will be available or will be at terms acceptable to the Company. The inability to raise capital as and when needed would have a negative impact on the Company’s liquidity, financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so. On November 10, 2022, the Company filed an omnibus shelf registration statement on Form S-3 that provides for the aggregate offerings of up to $ 50.0 9.7 10.80 On April 3, 2023, the Company completed a registered direct offering (“RDO”) utilizing its shelf registration statement for the purchase and sale of 1,557,632 1,947,040 The aggregate gross proceeds from this offer were $ 5.0 4.3 0.4 0.3 On January 26, 2024, the Company completed a private placement to 92 6.1 0.7 6,133,414 6,133,414 five years 511,940 five years 0.99 1.22 On April 11, 2024, the Company completed another private placement offering to 172 11.1 9.6 1.3 0.2 6,960,864 951,500 0.0001 7,912,364 1.22 5 3,956,182 1.22 2 701,243 1.69 5 The accompanying condensed interim financial statements have been prepared assuming that the Company will continue as a going concern and has reviewed the relevant conditions and events surrounding its ability to continue as a going concern including among others: historical losses, projected future results, negative cash flows from operations, including cash requirements for the upcoming year, funding capacity, net working capital, total stockholders’ equity and future access to capital. Based upon this review and the Company’s current financial condition and operating plans, the Company has concluded that these conditions raise substantial doubt regarding its ability to continue as a going concern for a period of at least one year from the date of issuance of these condensed interim financial statements. As a result, the Company will require additional funding to support its continuing operations. Until such time, if ever, as the Company can generate product revenue through its commercialization strategy, the Company expects to finance its cash needs through private or public equity financings, debt financings and collaborations, licenses or other similar arrangements. The Company continues to attract potential investors on the novel approach of its TAMP therapy platform.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Unaudited Condensed Interim Financial Information The accompanying unaudited condensed interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in unaudited condensed interim financial statements prepared in accordance with GAAP have been condensed or omitted. The unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The condensed balance sheet as of December 31, 2023, is derived from the Company’s audited financial statements. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the year ending December 31, 2024, or for any other future annual or interim period. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). There have been no material changes to the significant accounting policies during the nine months ended September 30, 2024 from those previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 1, 2024 (the “2023 Annual Report”) other than the accounting policies adopted in connection with the Company’s private placement offerings and the September Common Warrants as follows. In January and April of this year, the Company completed two private placement offerings issuing Common Stock, Pre-funded Common Warrants, Common Warrants and Placement Agent Warrants or (“PA Warrants”). The Company has applied the following accounting policies as it relates to each offering. January 2024 Private Placement The Company evaluated the Common Warrants and the PA Warrants issued in connection with the January offering in accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging – Contracts in Entity’s Own Entity April 2024 Private Placement The Company evaluated the Pre-funded Common Warrants, Common Warrants, (Series A and Series B), and the PA Warrants issued in connection with the April offering in accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging – Contracts in Entity’s Own Entity Earnings Per September 2024 Contract Manufacturing Organization Warrants In September 2024, the Company has issued a warrant to purchase up to 709,500 shares of the Company’s common stock (the “CMO Warrant”) as a performance incentive for the Company’s RenovoCath contract manufacturing organization, (“CMO”). The CMO Warrant vests and only becomes exercisable over time in tranches, and only if the CMO achieves certain manufacturing milestones. The Company evaluated the CMO Warrant in accordance with ASC 718, Compensation – Stock Compensation, and concluded the CMO Warrant constitutes share-based payments for goods used in the Company’s operations and the CMO Warrant is equity-classified, as it lacks characteristics that would require liability treatment, such as cash settlement provisions or obligations to repurchase shares. The fair value of the CMO Warrant will be measured using the Black-Scholes model, with grant date fair value determined by the award terms. As the CMO Warrant is an incentive under the Company’s commercial strategy for its RenovoCath device, the fair value of the CMO Warrant will be considered as part of the costs to produce the device as inventory and subsequently recognized as cost of sales upon the sale of associated goods. For the EPS treatment, management concluded that the CMO Warrant constitutes contingently issuable potential common shares. When shares are issued upon exercise of the CMO Warrant, the Company will assess dilutive effects per ASC 260, Earnings Per Share. Following ASC 260-10-45-22, the treasury stock method will apply, assuming warrant exercise at the start of each period (or issuance if later), and calculating incremental shares based on proceeds hypothetically used to repurchase shares at the average market price. Since the holder of the CMO Warrant does not participate in dividends with common stock pre-exercise, the shares of common stock underlying the CMO Warrant does not affect basic EPS until exercised. Risks and Uncertainties The Company is subject to a number of risks associated with companies at a similar stage, including the risks associated with the development of products that must receive regulatory approval before market launch, dependence on key individuals, competition from larger and more established companies, volatility of the industry, ability to obtain adequate financing to support the Company’s business plan, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company and general economic conditions. The Company is subject to a number of risks similar to other clinical-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical studies or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals and insurance coding for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, protection of its proprietary technology, and the need to secure and maintain adequate manufacturing arrangements with third parties. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses as well as the disclosure of contingent assets and liabilities, at the date of the financial statements during the reporting periods. In preparing these financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to, accruals of certain liabilities, including clinical trial accruals and other contingences, the valuation of financial instruments, the fair value of the Company’s common stock and the fair value of options granted under the Company’s equity incentive plan. On an ongoing basis, the Company evaluates its estimates, including those related to the fair values of assets, stock-based compensation, clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from these estimates. Emerging Growth Company and Smaller Reporting Company Status The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of the JOBS Act exempts emerging growth companies from complying with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. The Company is also a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act. If the Company is a smaller reporting company at the time the Company ceases to be an emerging growth company, the Company may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, the Company may choose to present only the two most recent fiscal years of audited financial statements in its Annual Report on Form 10-K and, like emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. ASU 2024-03 requires additional disclosures and disaggregation of certain costs and expenses on an interim and annual basis in the notes to the financial statements. ASU 2024-03 is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on its financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, “Improvement to income tax disclosures (Topic 740)”. ASU 2023-09 requires consistent categories and greater disaggregation of information in the income tax rate reconciliation as well as a disaggregation of taxes paid by jurisdiction for the income taxes paid. ASU 2023-09 is required to be adopted by the Company for annual periods beginning after December 15, 2024. Early adoption is permitted for annual consolidated financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the ASU, but does not expect any material impact upon adoption. In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” ASU 2023-07 is intended to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses, as well as how the chief operating decision maker uses the reported measure(s) of segment profit or loss in assessing performance. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is to be applied retrospectively to all periods presented in the financial statements. The Company is currently evaluating the potential impact of adopting this new guidance on its financial statements and disclosures. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326)” “ASU 2016-13”) . In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20)” and “Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) (ASU 2020-06): Accounting for Convertible Instruments and Contracts in an Entity,” which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The updated guidance is effective on a prospective basis for annual reporting periods beginning after December 15, 2023 and for interim periods within those periods. The Company early adopted this guidance as of January 1, 2022 and the pronouncement did not have any material impact on the Company’s financial position or results of operations.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements As of September 30, 2024, and December 31, 2023, the Company held $ 9.1 0.9 The following tables summarize the Company’s financial assets and liabilities, measured at fair value on a recurring basis by level within the fair value hierarchy, as of September 30, 2024, and December 31, 2023 (in thousands): Schedule of Financial Assets and Liabilities at Fair Value on Recurring Basis September 30, 2024 Assets Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 9,099 $ - $ - $ 9,099 $ 9,099 $ - $ - $ 9,099 Liabilities Level 1 Level 2 Level 3 Total Common stock warrant liability $ - $ - $ 1,188 $ 1,188 $ - $ - $ 1,188 $ 1,188 December 31, 2023 Assets Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 905 $ - $ - $ 905 $ 905 $ - $ - $ 905 Liabilities Level 1 Level 2 Level 3 Total Common stock warrant liability $ - $ - $ 3,291 $ 3,291 $ - $ - $ 3,291 $ 3,291 There were no transfers between Level 1, Level 2 or Level 3 during the periods presented. The Company had no other financial assets or liabilities that were required to be measured at fair value on a recurring basis. Assumptions Used in Determining Fair Value of Warrant The terms of the April 2023 Warrant April 2023 Warrant April 2023 Warrants The Company recorded the fair value of the April 2023 Warrant April 2023 Warrant April 2023 Warrant The fair value of the warrants was measured using a combination of Black-Scholes option pricing and Monte Carlo Simulation models that take into consideration probability factors of the various outcomes related to the exercise terms of the warrants using the following inputs: Schedule of Assumptions to Record Fair Value of Warrants September 30, 2024 December 31, 2023 Expected volatility 100 111 % 116 177 % Expected term (years) 0 4.01 1.01 4.76 Risk-free interest rate 3.58 4.73 % 3.86 4.78 % Dividend rate – % – % Changes on Level 3 Liabilities Measured at Fair Value on a Recurring Basis The following table reflects the change in the Company’s Level 3 liability associated with the April 2023 Warrant for the nine months ended September 30, 2024 (in thousands): Schedule of Level 3 Liabilities Measured at Fair Value on a Recurring Basis Fair value as of December 31, 2023 $ 3,291 Change in fair value (2,103 ) Fair value as of September 30, 2024 $ 1,188

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses The components of accrued expenses as of September 30, 2024, and December 31, 2023 are as follows (in thousands): Schedule of Accrued Expenses September 30, 2024 December 31, 2023 Clinical trial $ 495 $ 470 Employee benefits 568 75 Other 23 69 Total accrued expenses $ 1,086 $ 614

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Legal Proceedings From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the nine months ended September 30, 2024, and no material legal proceedings are subsequently outstanding or pending. Guarantees and Indemnification In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and directors. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company is not currently aware of any indemnification claims. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of September 30, 2024. Operating Leases The Company leases its headquarters in Los Altos, California under a month-to-month operating lease agreement. Rent expenses were $ 21,000 and $ 18,000 for the three months ended September 30, 2024, and 2023, respectively. Rent expenses were $ 62,000 and $ 55,000 for the nine months ended September 30, 2024, and 2023, respectively.

Equity Incentive Plan _ Stock-B

Equity Incentive Plan – Stock-Based Compensation Expense and Warrants	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plan – Stock-Based Compensation Expense and Warrants	6. Equity Incentive Plan – Stock-Based Compensation Expense and Warrants 2021 Omnibus Equity Incentive Plan On July 19, 2021, the Company’s Board of Directors adopted the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “2021 Plan”). The 2021 Plan, which became effective immediately prior to the closing of the IPO, initially reserved 2,185,832 10,832 320,807 A summary of the stock option activity for the nine months ended September 30, 2024 is as follows: Summary of Stock Option Award Activity Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2023 1,860,125 $ 2.47 7.24 $ 984 Granted 1,393,634 $ 1.18 - $ - Exercised (93,481 ) $ 0.74 - $ - Forfeited (334,371 ) $ 1.97 - $ - Expired (107,278 ) $ 2.50 - $ - Outstanding as of September 30, 2024 2,718,629 $ 1.93 7.76 $ 195 Exercisable as of September 30, 2024 1,446,266 $ 2.12 6.56 $ 193 Vested and expected to vest as of September 30, 2024 2,718,629 $ 1.93 7.76 $ 195 As of September 30, 2024, there was $ 1.8 2.90 For the nine months ended September 30, 2024, and 2023, the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock option granted. The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: Summary of Weighted-Average Assumptions Used to Calculate Fair Value of Stock Options Granted Nine Months Ended September 30, 2024 2023 Expected volatility 123.76 143.10 % 99.49 106.69 % Expected term (years) 6.02 10.00 6.02 10.00 Risk-free interest rate 3.63 4.30 % 3.40 4.28 % Dividend rate – % – % During the three months ended September 30, 2024, and 2023, the Company recognized $ 255,000 239,000 922,000 857,000 The following table summarizes the components of stock-based compensation expense recognized in the Company’s Condensed Statements of Operations during the three and nine months ended September 30, 2024, and 2023 (in thousands): Schedule of Stock-Based Compensation Expense Recognized 2024 2023 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Research and development $ 87 $ 46 $ 294 $ 155 General and administrative 168 193 628 702 Total stock-based compensation expense $ 255 $ 239 $ 922 $ 857 Restricted Stock Units and Restricted Stock Awards Issued for Services Restricted stock units (“RSU”) are valued based on the closing price of the Company’s common stock on the date of the grant. The fair value of RSU is recognized and amortized on a straight-line basis over the requisite service period of the award. The following table summarizes RSU activity during the nine months ended September 30, 2024: Schedule of Restricted Stock Units Shares Weighted- Outstanding as of December 31, 2023 - $ - Granted 5,000 $ 1.47 Vested (5,000 ) $ 1.47 Forfeiture - $ - Outstanding as of September 30, 2024 - $ - In March 2024, the Company issued 120,000 27,000 2024 Common Warrants In connection with the Company’s January 2024 private placement offering, the Company issued warrants to purchase up to 6,133,414 511,940 January 26, 2029 In connection with the Company’s April 2024 private placement offering, the Company issued pre-funded warrants to purchase 951,500 7,912,364 3,956,182 701,243 April 11, 2026 April 10, 2029 The following is a summary of the common stock warrant activity during the three months ended September 30, 2024. Schedule of Common Stock Warrant Activity Shares Weighted- Weighted- Aggregate Outstanding as of December 31, 2023 4,734,035 $ 7.68 3.51 $ 36,350 Issued in January 2024 to: Investors 5,961,286 $ 0.99 4.32 $ 5,901 Placement agency 511,940 $ 0.99 N/A $ 507 Insiders 172,128 $ 1.22 4.32 $ 210 Issued in April 2024 to: Investors 11,868,546 $ 1.22 3.53 $ 14,480 Investors (Pre-funded) 951,500 $ 0.0001 N/A $ - Placement agency 701,243 $ 1.69 4.53 $ 1,185 Exercised - $ - - $ - Expired - $ - - $ - Outstanding as of September 30, 2024 24,900,678 $ 2.35 3.61 $ 58,633

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes The Company had no income tax expense for the three and nine months ended September 30, 2024, and 2023. The Company’s effective income tax rate was 0 The Company’s policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. For the three and nine months ended September 30, 2024, and 2023, the Company had no

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	8. Net Loss Per Share Basic and diluted net loss per common share was calculated as follows (in thousands except per share amounts): Schedule of Computation of Basic and Diluted Net Loss Per Share 2024 2023 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Numerator: Net loss $ (2,471 ) $ (1,421 ) $ (5,936 ) $ (7,005 ) Denominator: Weighted average shares used in computing net loss per share – basic and diluted 24,940,746 10,693,080 21,325,695 10,154,914 Net loss per share – basic and diluted $ (0.10 ) $ (0.13 ) $ (0.28 ) $ (0.69 ) For the three and nine months ended September 30, 2024, and 2023, the Company had a net loss and as such, all outstanding shares of potentially dilutive securities were excluded from the calculation of diluted net loss per share as the inclusion would be anti-dilutive. Potentially dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows (in common stock equivalent shares): Schedule of Potentially Anti Dilutive Securities 2024 2023 As of September 30, 2024 2023 Options to purchase common stock 397,025 453,346 Common stock warrants 6,473,226 - Total 6,870,251 453,346

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	9. Related Party Transactions The Company has a consulting agreement with one of the Company’s co-founders, Dr. Ramtin Agah, pursuant to which Dr. Agah provides consulting services as the Company’s Chief Medical Officer by overseeing Company-sponsored clinical trials. For the three months ended September 30, 2024, and 2023, consulting fees paid to Dr. Agah were $ 76,000 228,000 49,000 91,000

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events On October 24, 2024, the Company entered into a lease agreement for new headquarters office space located in Mountain View, California, consisting of approximately 1,900 10,000 7,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Unaudited Condensed Interim Financial Information	Basis of Presentation and Unaudited Condensed Interim Financial Information The accompanying unaudited condensed interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in unaudited condensed interim financial statements prepared in accordance with GAAP have been condensed or omitted. The unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The condensed balance sheet as of December 31, 2023, is derived from the Company’s audited financial statements. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the year ending December 31, 2024, or for any other future annual or interim period. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). There have been no material changes to the significant accounting policies during the nine months ended September 30, 2024 from those previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 1, 2024 (the “2023 Annual Report”) other than the accounting policies adopted in connection with the Company’s private placement offerings and the September Common Warrants as follows. In January and April of this year, the Company completed two private placement offerings issuing Common Stock, Pre-funded Common Warrants, Common Warrants and Placement Agent Warrants or (“PA Warrants”). The Company has applied the following accounting policies as it relates to each offering. January 2024 Private Placement The Company evaluated the Common Warrants and the PA Warrants issued in connection with the January offering in accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging – Contracts in Entity’s Own Entity April 2024 Private Placement The Company evaluated the Pre-funded Common Warrants, Common Warrants, (Series A and Series B), and the PA Warrants issued in connection with the April offering in accordance with ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging – Contracts in Entity’s Own Entity Earnings Per September 2024 Contract Manufacturing Organization Warrants In September 2024, the Company has issued a warrant to purchase up to 709,500 shares of the Company’s common stock (the “CMO Warrant”) as a performance incentive for the Company’s RenovoCath contract manufacturing organization, (“CMO”). The CMO Warrant vests and only becomes exercisable over time in tranches, and only if the CMO achieves certain manufacturing milestones. The Company evaluated the CMO Warrant in accordance with ASC 718, Compensation – Stock Compensation, and concluded the CMO Warrant constitutes share-based payments for goods used in the Company’s operations and the CMO Warrant is equity-classified, as it lacks characteristics that would require liability treatment, such as cash settlement provisions or obligations to repurchase shares. The fair value of the CMO Warrant will be measured using the Black-Scholes model, with grant date fair value determined by the award terms. As the CMO Warrant is an incentive under the Company’s commercial strategy for its RenovoCath device, the fair value of the CMO Warrant will be considered as part of the costs to produce the device as inventory and subsequently recognized as cost of sales upon the sale of associated goods. For the EPS treatment, management concluded that the CMO Warrant constitutes contingently issuable potential common shares. When shares are issued upon exercise of the CMO Warrant, the Company will assess dilutive effects per ASC 260, Earnings Per Share. Following ASC 260-10-45-22, the treasury stock method will apply, assuming warrant exercise at the start of each period (or issuance if later), and calculating incremental shares based on proceeds hypothetically used to repurchase shares at the average market price. Since the holder of the CMO Warrant does not participate in dividends with common stock pre-exercise, the shares of common stock underlying the CMO Warrant does not affect basic EPS until exercised.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to a number of risks associated with companies at a similar stage, including the risks associated with the development of products that must receive regulatory approval before market launch, dependence on key individuals, competition from larger and more established companies, volatility of the industry, ability to obtain adequate financing to support the Company’s business plan, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company and general economic conditions. The Company is subject to a number of risks similar to other clinical-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical studies or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals and insurance coding for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, protection of its proprietary technology, and the need to secure and maintain adequate manufacturing arrangements with third parties.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses as well as the disclosure of contingent assets and liabilities, at the date of the financial statements during the reporting periods. In preparing these financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to, accruals of certain liabilities, including clinical trial accruals and other contingences, the valuation of financial instruments, the fair value of the Company’s common stock and the fair value of options granted under the Company’s equity incentive plan. On an ongoing basis, the Company evaluates its estimates, including those related to the fair values of assets, stock-based compensation, clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from these estimates.
Emerging Growth Company and Smaller Reporting Company Status	Emerging Growth Company and Smaller Reporting Company Status The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of the JOBS Act exempts emerging growth companies from complying with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. The Company is also a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act. If the Company is a smaller reporting company at the time the Company ceases to be an emerging growth company, the Company may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, the Company may choose to present only the two most recent fiscal years of audited financial statements in its Annual Report on Form 10-K and, like emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. ASU 2024-03 requires additional disclosures and disaggregation of certain costs and expenses on an interim and annual basis in the notes to the financial statements. ASU 2024-03 is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on its financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, “Improvement to income tax disclosures (Topic 740)”. ASU 2023-09 requires consistent categories and greater disaggregation of information in the income tax rate reconciliation as well as a disaggregation of taxes paid by jurisdiction for the income taxes paid. ASU 2023-09 is required to be adopted by the Company for annual periods beginning after December 15, 2024. Early adoption is permitted for annual consolidated financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the ASU, but does not expect any material impact upon adoption. In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” ASU 2023-07 is intended to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses, as well as how the chief operating decision maker uses the reported measure(s) of segment profit or loss in assessing performance. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is to be applied retrospectively to all periods presented in the financial statements. The Company is currently evaluating the potential impact of adopting this new guidance on its financial statements and disclosures.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses (Topic 326)” “ASU 2016-13”) . In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20)” and “Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) (ASU 2020-06): Accounting for Convertible Instruments and Contracts in an Entity,” which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The updated guidance is effective on a prospective basis for annual reporting periods beginning after December 15, 2023 and for interim periods within those periods. The Company early adopted this guidance as of January 1, 2022 and the pronouncement did not have any material impact on the Company’s financial position or results of operations.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities at Fair Value on Recurring Basis	The following tables summarize the Company’s financial assets and liabilities, measured at fair value on a recurring basis by level within the fair value hierarchy, as of September 30, 2024, and December 31, 2023 (in thousands): Schedule of Financial Assets and Liabilities at Fair Value on Recurring Basis September 30, 2024 Assets Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 9,099 $ - $ - $ 9,099 $ 9,099 $ - $ - $ 9,099 Liabilities Level 1 Level 2 Level 3 Total Common stock warrant liability $ - $ - $ 1,188 $ 1,188 $ - $ - $ 1,188 $ 1,188 December 31, 2023 Assets Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 905 $ - $ - $ 905 $ 905 $ - $ - $ 905 Liabilities Level 1 Level 2 Level 3 Total Common stock warrant liability $ - $ - $ 3,291 $ 3,291 $ - $ - $ 3,291 $ 3,291
Schedule of Assumptions to Record Fair Value of Warrants	The fair value of the warrants was measured using a combination of Black-Scholes option pricing and Monte Carlo Simulation models that take into consideration probability factors of the various outcomes related to the exercise terms of the warrants using the following inputs: Schedule of Assumptions to Record Fair Value of Warrants September 30, 2024 December 31, 2023 Expected volatility 100 111 % 116 177 % Expected term (years) 0 4.01 1.01 4.76 Risk-free interest rate 3.58 4.73 % 3.86 4.78 % Dividend rate – % – %
Schedule of Level 3 Liabilities Measured at Fair Value on a Recurring Basis	The following table reflects the change in the Company’s Level 3 liability associated with the April 2023 Warrant for the nine months ended September 30, 2024 (in thousands): Schedule of Level 3 Liabilities Measured at Fair Value on a Recurring Basis Fair value as of December 31, 2023 $ 3,291 Change in fair value (2,103 ) Fair value as of September 30, 2024 $ 1,188

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	The components of accrued expenses as of September 30, 2024, and December 31, 2023 are as follows (in thousands): Schedule of Accrued Expenses September 30, 2024 December 31, 2023 Clinical trial $ 495 $ 470 Employee benefits 568 75 Other 23 69 Total accrued expenses $ 1,086 $ 614

Equity Incentive Plan _ Stock_2

Equity Incentive Plan – Stock-Based Compensation Expense and Warrants (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Award Activity	A summary of the stock option activity for the nine months ended September 30, 2024 is as follows: Summary of Stock Option Award Activity Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2023 1,860,125 $ 2.47 7.24 $ 984 Granted 1,393,634 $ 1.18 - $ - Exercised (93,481 ) $ 0.74 - $ - Forfeited (334,371 ) $ 1.97 - $ - Expired (107,278 ) $ 2.50 - $ - Outstanding as of September 30, 2024 2,718,629 $ 1.93 7.76 $ 195 Exercisable as of September 30, 2024 1,446,266 $ 2.12 6.56 $ 193 Vested and expected to vest as of September 30, 2024 2,718,629 $ 1.93 7.76 $ 195
Summary of Weighted-Average Assumptions Used to Calculate Fair Value of Stock Options Granted	For the nine months ended September 30, 2024, and 2023, the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock option granted. The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: Summary of Weighted-Average Assumptions Used to Calculate Fair Value of Stock Options Granted Nine Months Ended September 30, 2024 2023 Expected volatility 123.76 143.10 % 99.49 106.69 % Expected term (years) 6.02 10.00 6.02 10.00 Risk-free interest rate 3.63 4.30 % 3.40 4.28 % Dividend rate – % – %
Schedule of Stock-Based Compensation Expense Recognized	The following table summarizes the components of stock-based compensation expense recognized in the Company’s Condensed Statements of Operations during the three and nine months ended September 30, 2024, and 2023 (in thousands): Schedule of Stock-Based Compensation Expense Recognized 2024 2023 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Research and development $ 87 $ 46 $ 294 $ 155 General and administrative 168 193 628 702 Total stock-based compensation expense $ 255 $ 239 $ 922 $ 857
Schedule of Restricted Stock Units	The following table summarizes RSU activity during the nine months ended September 30, 2024: Schedule of Restricted Stock Units Shares Weighted- Outstanding as of December 31, 2023 - $ - Granted 5,000 $ 1.47 Vested (5,000 ) $ 1.47 Forfeiture - $ - Outstanding as of September 30, 2024 - $ -
Schedule of Common Stock Warrant Activity	The following is a summary of the common stock warrant activity during the three months ended September 30, 2024. Schedule of Common Stock Warrant Activity Shares Weighted- Weighted- Aggregate Outstanding as of December 31, 2023 4,734,035 $ 7.68 3.51 $ 36,350 Issued in January 2024 to: Investors 5,961,286 $ 0.99 4.32 $ 5,901 Placement agency 511,940 $ 0.99 N/A $ 507 Insiders 172,128 $ 1.22 4.32 $ 210 Issued in April 2024 to: Investors 11,868,546 $ 1.22 3.53 $ 14,480 Investors (Pre-funded) 951,500 $ 0.0001 N/A $ - Placement agency 701,243 $ 1.69 4.53 $ 1,185 Exercised - $ - - $ - Expired - $ - - $ - Outstanding as of September 30, 2024 24,900,678 $ 2.35 3.61 $ 58,633

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per common share was calculated as follows (in thousands except per share amounts): Schedule of Computation of Basic and Diluted Net Loss Per Share 2024 2023 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Numerator: Net loss $ (2,471 ) $ (1,421 ) $ (5,936 ) $ (7,005 ) Denominator: Weighted average shares used in computing net loss per share – basic and diluted 24,940,746 10,693,080 21,325,695 10,154,914 Net loss per share – basic and diluted $ (0.10 ) $ (0.13 ) $ (0.28 ) $ (0.69 )
Schedule of Potentially Anti Dilutive Securities	Potentially dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows (in common stock equivalent shares): Schedule of Potentially Anti Dilutive Securities 2024 2023 As of September 30, 2024 2023 Options to purchase common stock 397,025 453,346 Common stock warrants 6,473,226 - Total 6,870,251 453,346

Business and Principal Activi_2

Business and Principal Activities (Details Narrative) $ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

Apr. 11, 2024 USD ($) Investor $ / shares shares

Jan. 26, 2024 USD ($) Investor $ / shares shares

Apr. 03, 2023 USD ($) shares

Nov. 10, 2022 USD ($) $ / shares

Sep. 30, 2024 USD ($) $ / shares

Jun. 30, 2024 USD ($) shares

Mar. 31, 2024 USD ($) shares

Sep. 30, 2023 USD ($)

Jun. 30, 2023 USD ($) shares

Mar. 31, 2023 USD ($)

Sep. 30, 2024 USD ($) $ / shares

Sep. 30, 2023 USD ($)

Dec. 31, 2023 USD ($) $ / shares

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Proceeds from sale of equity

$ 59,200

Net proceeds from offerings

$ 53,800

53,800

Cash and cash equivalents

$ 9,563

$ 9,563

$ 1,173

Common stock, par value | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

Net loss

$ 2,471

$ 2,389

$ 1,076

$ 1,421

$ 2,327

$ 3,257

$ 5,936

$ 7,005

Accumulated deficit

47,341

47,341

$ 41,405

Maximum possible proceeds from offerings

$ 50,000

9,700

Threshold per share limit for exercise of warrants | $ / shares

$ 10.80

Gross proceeds from registered direct offering

$ 5,000

Net proceeds from registered direct offering

4,300

Placement agent fees

400

Other professional expenses

$ 300

Gross proceeds from private placement

$ 15,016

$ 5,000

Common Stock [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Net loss

Number of common stock issued | shares

6,960,864

6,133,414

1,000,000

Prefunded Common Stock Warrants [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Sale of common stock | shares

1,557,632

April 2023 Common Warrant [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants to purchase common stock | shares

1,947,040

Private Placement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants to purchase common stock | shares

701,243

Number of accredited investors | Investor

172

92

Gross proceeds from private placement

$ 11,100

$ 6,100

Other professional expenses

$ 200

$ 700

Number of common stock issued | shares

6,133,414

Warrants rights term

5 years

5 years

Warrants exercise price | $ / shares

$ 1.69

$ 0.99

Net proceeds from offering

$ 9,600

Placement agent fees

$ 1,300

Private Placement [Member] | Common Stock [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Number of common stock issued | shares

6,960,864

Private Placement [Member] | Prefunded Common Stock Warrants [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants to purchase common stock | shares

951,500

Warrants exercise price | $ / shares

$ 0.0001

Private Placement [Member] | Series A Warrants [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants to purchase common stock | shares

7,912,364

Warrants rights term

5 years

Warrants exercise price | $ / shares

$ 1.22

Private Placement [Member] | Series B Warrants [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants to purchase common stock | shares

3,956,182

Warrants rights term

2 years

Warrants exercise price | $ / shares

$ 1.22

Private Placement [Member] | Director [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants exercise price | $ / shares

1.22

Private Placement [Member] | Officer [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants exercise price | $ / shares

1.22

Private Placement [Member] | Employees [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants exercise price | $ / shares

1.22

Private Placement [Member] | Consultants [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants exercise price | $ / shares

$ 1.22

Private Placement [Member] | Placement Agent Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants rights term

5 years

January 2024 Common Warrants [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants to purchase common stock | shares

6,133,414

January 2024 PA Warrants [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Warrants to purchase common stock | shares

511,940

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative)	Sep. 30, 2024 shares
September 2024 RenovoCath Contract Manufacturing Organization Warrants [Member] | Maximum [Member]
PerformanceIncentiveLineItem [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	709,500

Schedule of Financial Assets an

Schedule of Financial Assets and Liabilities at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 9,099	$ 905
Fair value of liabilities	1,188	3,291
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	9,099	905
Common Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	1,188	3,291
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	9,099	905
Fair value of liabilities
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	9,099	905
Fair Value, Inputs, Level 1 [Member] | Common Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets
Fair Value, Inputs, Level 2 [Member] | Common Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets
Fair value of liabilities	1,188	3,291
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets
Fair Value, Inputs, Level 3 [Member] | Common Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	$ 1,188	$ 3,291

Schedule of Assumptions to Reco

Schedule of Assumptions to Record Fair Value of Warrants (Details)	Sep. 30, 2024	Dec. 31, 2023
Measurement Input, Option Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	100	116
Measurement Input, Option Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	111	177
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (years)	0 years	1 year 3 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (years)	4 years 3 days	4 years 9 months 3 days
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	3.58	3.86
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	4.73	4.78
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants measurement input	0	0

Schedule of Level 3 Liabilities

Schedule of Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value	$ (2,103)	$ (3,092)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value as of December 31, 2023	3,291
Change in fair value	(2,103)
Fair value as of September 30, 2024	$ 1,188

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Money market funds, at carrying value	$ 9.1	$ 0.9

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Clinical trial	$ 495	$ 470
Employee benefits	568	75
Other	23	69
Total accrued expenses	$ 1,086	$ 614

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Description			The Company leases its headquarters in Los Altos, California under a month-to-month operating lease agreement.
Rent expense	$ 21,000	$ 18,000	$ 62,000	$ 55,000

Summary of Stock Option Award A

Summary of Stock Option Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Number of stock options outstanding, beginning balance	1,860,125
Weighted average exercise price outstanding, beginning balance	$ 2.47
Weighted average remaining contractual life	7 years 9 months 3 days	7 years 2 months 26 days
Aggregate intrinsic value outstanding, beginning balance	$ 984
Number of stock options, granted	1,393,634
Weighted average exercise price, granted	$ 1.18
Number of stock options, exercised	(93,481)
Weighted average exercise price, exercised	$ 0.74
Number of stock options, forfeited	(334,371)
Weighted average exercise price, forfeited	$ 1.97
Number of stock options, expired	(107,278)
Weighted average exercise price, expired	$ 2.50
Number of stock options outstanding, ending balance	2,718,629	1,860,125
Weighted average exercise price outstanding, ending balance	$ 1.93	$ 2.47
Aggregate intrinsic value outstanding, ending balance	$ 195	$ 984
Number of stock options, exercisable	1,446,266
Weighted average exercise price, exercisable	$ 2.12
Weighted average remaining contractual life, exercisable	6 years 6 months 21 days
Aggregate intrinsic value, exercisable	$ 193
Number of stock options, vested and expected to vest	2,718,629
Weighted average exercise price, vested and expected to vest	$ 1.93
Weighted average remaining contractual life, vested and expected to vest	7 years 9 months 3 days
Aggregate intrinsic value, vested and expected to vest	$ 195

Summary of Weighted-Average Ass

Summary of Weighted-Average Assumptions Used to Calculate Fair Value of Stock Options Granted (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility rate, minimum	123.76%	99.49%
Expected volatility rate, maximum	143.10%	106.69%
Risk-free interest rate, minimum	3.63%	3.40%
Risk-free interest rate, maximum	4.30%	4.28%
Dividend rate	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)	6 years 7 days	6 years 7 days
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)	10 years	10 years

Schedule of Stock-Based Compens

Schedule of Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 255	$ 239	$ 922	$ 857
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	87	46	294	155
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 168	$ 193	$ 628	$ 702

Schedule of Restricted Stock Un

Schedule of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock units, beginning balance | shares
Weighted average exercise price, beginning balance | $ / shares
Number of restricted stock units, granted | shares	5,000
Weighted average exercise price, granted | $ / shares	$ 1.47
Number of restricted stock units, vested | shares	(5,000)
Weighted average exercise price, vested | $ / shares	$ 1.47
Number of restricted stock units, forfeiture | shares
Weighted average exercise price, forfeiture | $ / shares
Number of restricted stock units, ending balance | shares
Weighted average exercise price, ending balance | $ / shares

Schedule of Common Stock Warran

Schedule of Common Stock Warrant Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, beginning balance | shares	4,734,035
Weighted average exercise price, beginning balance | $ / shares	$ 7.68
Weighted average remaining contractual life, beginning	3 years 6 months 3 days
Warrants aggregate intrinsic value, beginning balance | $	$ 36,350
Warrants outstanding, exercised | shares
Weighted average exercise price, exercised | $ / shares
Warrants outstanding, expired | shares
Weighted average exercise price, expired | $ / shares
Warrants outstanding, ending balance | shares	24,900,678
Weighted average exercise price, ending balance | $ / shares	$ 2.35
Weighted average remaining contractual life, ending	3 years 7 months 9 days
Warrants aggregate intrinsic value, ending balance | $	$ 58,633
Investors [Member] | January 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, issued | shares	5,961,286
Weighted average exercise price, issued | $ / shares	$ 0.99
Weighted average remaining contractual life, issued	4 years 3 months 25 days
Warrants aggregate intrinsic value, issued | $	$ 5,901
Investors [Member] | April 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, issued | shares	11,868,546
Weighted average exercise price, issued | $ / shares	$ 1.22
Weighted average remaining contractual life, issued	3 years 6 months 10 days
Warrants aggregate intrinsic value, issued | $	$ 14,480
Placement Agency [Member] | January 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, issued | shares	511,940
Weighted average exercise price, issued | $ / shares	$ 0.99
Warrants aggregate intrinsic value, issued | $	$ 507
Placement Agency [Member] | April 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, issued | shares	701,243
Weighted average exercise price, issued | $ / shares	$ 1.69
Weighted average remaining contractual life, issued	4 years 6 months 10 days
Warrants aggregate intrinsic value, issued | $	$ 1,185
Insiders [Member] | January 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, issued | shares	172,128
Weighted average exercise price, issued | $ / shares	$ 1.22
Weighted average remaining contractual life, issued	4 years 3 months 25 days
Warrants aggregate intrinsic value, issued | $	$ 210
Pre Funded Investors [Member] | April 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, issued | shares	951,500
Weighted average exercise price, issued | $ / shares	$ 0.0001
Warrants aggregate intrinsic value, issued | $

Equity Incentive Plan _ Stock_3

Equity Incentive Plan – Stock-Based Compensation Expense and Warrants (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Apr. 11, 2024	Jan. 26, 2024	Jan. 01, 2024	Jul. 19, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized stock based compensation expense		$ 1,800,000		$ 1,800,000
Weighted average period of recognition				2 years 10 months 24 days
Stock-based compensation expense		255,000	$ 239,000	$ 922,000	$ 857,000
Share based compensation		$ 255,000	$ 239,000	$ 922,000	$ 857,000
January 2024 Common Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase common stock							6,133,414
January 2024 PA Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase common stock							511,940
Warrants expiration date							Jan. 26, 2029
Private Placement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase common stock						701,243
Warrants expiration date						Apr. 10, 2029
Private Placement [Member] | Prefunded Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase common stock						951,500
Warrants expiration date						Apr. 10, 2029
Private Placement [Member] | Series A Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase common stock						7,912,364
Warrants expiration date						Apr. 10, 2029
Private Placement [Member] | Series B Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase common stock						3,956,182
Warrants expiration date						Apr. 11, 2026
2021 Omnibus Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved and available for issuance								320,807	2,185,832
Amended and Restated 2013 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common shares reserved but unissued									10,832
2021 Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of restricted stock awards, shares	120,000
Share based compensation	$ 27,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	0%		0%
Accrued interest or penalties related to uncertain tax positions	$ 0	$ 0	$ 0	$ 0

Schedule of Computation of Basi

Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net loss	$ (2,471)	$ (2,389)	$ (1,076)	$ (1,421)	$ (2,327)	$ (3,257)	$ (5,936)	$ (7,005)
Weighted average shares used in computing net loss per share - basic	24,940,746			10,693,080			21,325,695	10,154,914
Weighted average shares used in computing net loss per share - diluted	24,940,746			10,693,080			21,325,695	10,154,914
Net loss per share - basic	$ (0.10)			$ (0.13)			$ (0.28)	$ (0.69)
Net loss per share - diluted	$ (0.10)			$ (0.13)			$ (0.28)	$ (0.69)

Schedule of Potentially Anti Di

Schedule of Potentially Anti Dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,870,251	453,346
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	397,025	453,346
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,473,226

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Dr. Agah [Member] - Consulting Agreement [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	May 31, 2024	Feb. 28, 2023
Related Party Transaction [Line Items]
Consulting fees	$ 76,000	$ 76,000	$ 228,000	$ 228,000
Discretionary bonus					$ 49,000	$ 91,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Lease Agreement [Member]	Oct. 24, 2024 USD ($) ft²
Subsequent Event [Line Items]
Area of land | ft²	1,900
Payments for rent	$ 10,000
Los Altos California [Member]
Subsequent Event [Line Items]
Payments for rent	$ 7,000